This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Feb;12(2):61.

doi: 10.1038/nrurol.2014.344. Epub 2014 Dec 16.

Bladder cancer: Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?

PMID: 25512206
DOI: 10.1038/nrurol.2014.344

Comment

Bladder cancer: Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?

Annette Fenner. Nat Rev Urol. 2015 Feb.

. 2015 Feb;12(2):61.

doi: 10.1038/nrurol.2014.344. Epub 2014 Dec 16.

Author

PMID: 25512206
DOI: 10.1038/nrurol.2014.344

No abstract available

PubMed Disclaimer

Comment on

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Powles T, et al. Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904. Nature. 2014. PMID: 25428503 Clinical Trial.

References

1. Nature. 2014 Nov 27;515(7528):558-62 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information